Association Pour Le Developpement Des Centres De Sante - Kersanté
- Address
- lock Available on a paid plan
Association Pour Le Developpement Des Centres De Sante - Kersanté
The Association Pour Le Developpement Des Centres De Sante - Kersanté is a clinical research facility focused on advancing cardiovascular disease prevention in high-risk patient populations. The center specializes in investigating novel therapeutic strategies for patients with type 2 diabetes who have not yet experienced cardiovascular events, addressing a critical gap in preventive cardiology.
- Cardiovascular disease prevention in diabetic populations without prior CV events
- Anti-inflammatory therapies including low-dose colchicine for cardiovascular risk reduction
- Antiplatelet therapy optimization with non-enteric coated aspirin formulations
- Combination therapy approaches for high-risk type 2 diabetes patients
The center's research program evaluates comprehensive cardiovascular outcomes including cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, and urgent hospitalization for angina requiring coronary revascularization. By investigating both individual and combined therapeutic interventions added to standard of care, the facility contributes to evidence-based strategies for preventing cardiovascular complications in diabetic patients at elevated risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Montreal Heart Institute1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Association Pour Le Developpement Des Centres De Sante - Kersanté
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Colchicine and Carbaspirin Calcium in Cardiovascular Outcomes for Type 2 Diabetes Patients Without Prior Cardiovascular Events | Montreal Heart Institute | Phase III | Recruiting | Aug 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carbasalate Calcium | 1 | Unknown | 2025-08-15 | 2025-08-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.